| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Kalpana Nagpal | Q37828639 |
| Shailendra Kumar Singh | Q37828647 | ||
| P2093 | author name string | Dina Nath Mishra | |
| P2860 | cites work | Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone | Q24595896 |
| Nanotechnology: intelligent design to treat complex disease | Q28246583 | ||
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q28842973 | ||
| Blood-brain barrier genomics | Q33270802 | ||
| Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles | Q33327252 | ||
| Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles | Q33355908 | ||
| The cell biology of the blood-brain barrier. | Q33593387 | ||
| Nanogels for oligonucleotide delivery to the brain | Q33725062 | ||
| Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. | Q33879575 | ||
| Nanoparticulate systems for brain delivery of drugs | Q33938252 | ||
| Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery | Q33955046 | ||
| Astrocyte-endothelial interactions and blood-brain barrier permeability | Q33960608 | ||
| In vivo near-infrared fluorescence imaging | Q33973447 | ||
| How to measure drug transport across the blood-brain barrier | Q33985116 | ||
| Endocytosis of nanomedicines. | Q33987301 | ||
| Solid lipid nanoparticles for targeted brain drug delivery | Q34004708 | ||
| Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system | Q34008653 | ||
| Proton transport across transient single-file water pores in a lipid membrane studied by molecular dynamics simulations | Q34040267 | ||
| SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers | Q44164523 | ||
| UEA I-bearing nanoparticles for brain delivery following intranasal administration | Q44201223 | ||
| Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate | Q44223183 | ||
| Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. | Q44225181 | ||
| Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles | Q44386469 | ||
| Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography | Q44529786 | ||
| Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. | Q45122051 | ||
| Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats | Q45803643 | ||
| Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles. | Q45923880 | ||
| Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles. | Q45968864 | ||
| Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. | Q45999514 | ||
| Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. | Q46033153 | ||
| Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution | Q46063843 | ||
| The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis | Q46102626 | ||
| Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). | Q46355807 | ||
| Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting | Q46442643 | ||
| Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies | Q46490341 | ||
| Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice | Q46514919 | ||
| Intranasal nanoemulsion based brain targeting drug delivery system of risperidone | Q46612913 | ||
| Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease | Q46740678 | ||
| Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity | Q46768039 | ||
| Feedback-regulated paclitaxel delivery based on poly(N,N-dimethylaminoethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles | Q46768171 | ||
| Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. | Q46803317 | ||
| Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier | Q46836311 | ||
| Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration | Q46970487 | ||
| Intrinsically fluorescent carbon nanospheres as a nuclear targeting vector: delivery of membrane-impermeable molecule to modulate gene expression in vivo. | Q47341033 | ||
| Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier | Q47988449 | ||
| Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles | Q48003121 | ||
| Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. | Q48096517 | ||
| Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology. | Q48169602 | ||
| Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain | Q48208372 | ||
| Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. | Q42967543 | ||
| Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging | Q43074512 | ||
| Evaluation of [11C]-DAA1106 for imaging and quantification of neuroinflammation in a rat model of herpes encephalitis | Q43178251 | ||
| Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses | Q43225836 | ||
| Preparation and evaluation of anti-neuroexcitation peptide (ANEP) loaded N-trimethyl chitosan chloride nanoparticles for brain-targeting | Q43245512 | ||
| Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain | Q43894483 | ||
| Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles | Q48211150 | ||
| 1-O-alkylglycerol stabilized carbamazepine intravenous o/w nanoemulsions for drug targeting in mice | Q48238599 | ||
| Nanoparticle mediated brain targeted delivery of gallic acid: in vivo behavioral and biochemical studies for improved antioxidant and antidepressant-like activity | Q48284169 | ||
| Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism | Q48356189 | ||
| Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo | Q48372285 | ||
| Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier | Q48408807 | ||
| Phospholipid based colloidal poloxamer-nanocubic vesicles for brain targeting via the nasal route. | Q48450160 | ||
| Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer | Q48455152 | ||
| The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats | Q48457386 | ||
| Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study | Q48466858 | ||
| Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier | Q48520343 | ||
| Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study | Q48536446 | ||
| Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels | Q48587261 | ||
| Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles | Q48589259 | ||
| Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. | Q48608387 | ||
| Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones | Q48706032 | ||
| Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting | Q48758897 | ||
| Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier | Q48774664 | ||
| Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. | Q48784173 | ||
| BBB-Genomics: creating new openings for brain-drug targeting | Q48919251 | ||
| Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery | Q49058125 | ||
| The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation | Q49106787 | ||
| Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections | Q49111527 | ||
| Carrier-mediated transport of the antitumor agent acivicin across the blood-brain barrier | Q49270919 | ||
| The formulation, characterization and in vivo evaluation of a magnetic carrier for brain delivery of NIR dye. | Q50541826 | ||
| The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. | Q51822661 | ||
| Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. | Q52607718 | ||
| Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models. | Q52960129 | ||
| Why is the global CNS pharmaceutical market so under-penetrated? | Q55035622 | ||
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q57001954 | ||
| Log(BB), PS products and in silico models of drug brain penetration | Q57677352 | ||
| Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats | Q59237516 | ||
| Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard | Q34053885 | ||
| A method to determine the ability of drugs to diffuse through the blood-brain barrier | Q34061126 | ||
| Role of the CNS microvascular pericyte in the blood-brain barrier | Q34067528 | ||
| Blood-brain barrier permeation: molecular parameters governing passive diffusion | Q34067620 | ||
| Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain | Q34124710 | ||
| Lipophilicity in PK design: methyl, ethyl, futile | Q34209458 | ||
| Adenosine receptor signaling modulates permeability of the blood-brain barrier. | Q34216355 | ||
| Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting | Q34258878 | ||
| Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification | Q34350623 | ||
| Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system | Q34388647 | ||
| Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration | Q34414515 | ||
| Molecular imprinting within hydrogels | Q34470016 | ||
| Apolipoprotein E: From lipid transport to neurobiology | Q34497951 | ||
| Permeability of the blood-brain barrier for atenolol studied by positron emission tomography | Q34543317 | ||
| Endocytosis of titanium dioxide nanoparticles in prostate cancer PC-3M cells. | Q34708980 | ||
| Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells | Q35003095 | ||
| Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation | Q35153612 | ||
| Molecular mechanism of endothelial growth arrest by laminar shear stress | Q35205740 | ||
| Hard and soft micromachining for BioMEMS: review of techniques and examples of applications in microfluidics and drug delivery | Q35637324 | ||
| A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity | Q35660849 | ||
| Is nose-to-brain transport of drugs in man a reality? | Q35673938 | ||
| In vitro blood-brain barrier models: current and perspective technologies | Q35782792 | ||
| Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection: trans-tissue, sustained local drug-delivery systems | Q35965296 | ||
| Astrocytes: regulation of brain homeostasis via apolipoprotein E. | Q36075053 | ||
| A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier | Q36267668 | ||
| The use of monolayers for simple and quantitative analysis of lipid-drug interactions exemplified with dibucaine and substance P | Q36580365 | ||
| Fluorescence imaging in vivo: recent advances | Q36711843 | ||
| Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery | Q36773586 | ||
| On the rate and extent of drug delivery to the brain. | Q37023904 | ||
| Strategies to advance translational research into brain barriers | Q37037950 | ||
| Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy | Q37154213 | ||
| PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter | Q37164698 | ||
| Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting | Q37182367 | ||
| Progress in drug delivery to the central nervous system by the prodrug approach. | Q37193593 | ||
| Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. | Q37395149 | ||
| Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases | Q37416147 | ||
| Gum arabic-coated magnetic nanoparticles for potential application in simultaneous magnetic targeting and tumor imaging | Q37433524 | ||
| Nanoparticles for direct nose-to-brain delivery of drugs. | Q37531152 | ||
| Brain drug targeting: a computational approach for overcoming blood-brain barrier | Q37568584 | ||
| Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases | Q37576225 | ||
| Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept | Q37638537 | ||
| Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots | Q37668250 | ||
| Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease | Q37668424 | ||
| In vitro blood-brain barrier models--latest advances and therapeutic applications in a chronological perspective. | Q37735241 | ||
| Strategy for effective brain drug delivery. | Q37760347 | ||
| In vivo methods to study uptake of nanoparticles into the brain. | Q37798178 | ||
| Transport of drugs across the blood-brain barrier by nanoparticles. | Q37923068 | ||
| Nanotechnological advances for the delivery of CNS therapeutics | Q37958426 | ||
| Modern methods for delivery of drugs across the blood-brain barrier | Q37966443 | ||
| Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases | Q38023097 | ||
| The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model | Q38448723 | ||
| Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. | Q39371382 | ||
| The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. | Q39408907 | ||
| Improved transnasal transport and brain uptake of tizanidine HCl-loaded thiolated chitosan nanoparticles for alleviation of pain. | Q39456726 | ||
| The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles | Q39680497 | ||
| Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats | Q39684569 | ||
| Evaluation of O-[(18)F]fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography | Q39867815 | ||
| Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery | Q39890616 | ||
| Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury | Q39942829 | ||
| Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity | Q39972148 | ||
| Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations | Q40081472 | ||
| Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma | Q40145038 | ||
| Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway | Q40340698 | ||
| Animal models for studying transport across the blood-brain barrier | Q40506058 | ||
| Paclitaxel nanoparticles for the potential treatment of brain tumors | Q40513384 | ||
| Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. | Q40639360 | ||
| Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays | Q40712615 | ||
| Magnetic targeting of nanoparticles across the intact blood-brain barrier | Q40954233 | ||
| Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. | Q42108498 | ||
| Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles | Q42458746 | ||
| Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug | Q42496777 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 927-955 | |
| P577 | publication date | 2013-01-21 | |
| P1433 | published in | Expert Opinion on Drug Delivery | Q5421203 |
| P1476 | title | Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB. | |
| P478 | volume | 10 |
| Q48818624 | A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine |
| Q36172940 | A Genetic Algorithm Based Support Vector Machine Model for Blood-Brain Barrier Penetration Prediction |
| Q38243893 | Activators of AMPK: not just for type II diabetes |
| Q38836486 | Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery |
| Q64997828 | Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood-brain barrier transport. |
| Q88128137 | Improved Prediction of Blood-Brain Barrier Permeability Through Machine Learning with Combined Use of Molecular Property-Based Descriptors and Fingerprints |
| Q38700355 | In Silico Prediction for Intestinal Absorption and Brain Penetration of Chemical Pesticides in Humans |
| Q48870977 | Influence of the formulation on the maximum tolerated doses of brain targeted nanoparticles of gallic acid by oral administration in Wistar rats |
| Q57570763 | Nanoparticle Functionalization for Brain Targeting Drug Delivery and Diagnostic |
| Q37698620 | Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system |
| Q28540914 | P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models |
| Q36020685 | Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations |
| Q92798768 | Recent expansions of novel strategies towards the drug targeting into the brain |
| Q44106992 | Targeted delivery of drugs to the brain. |
Search more.